U životinjskim studijama, je pokazano da naftilizopropilamin redukujekokainskusamoadministraciju, mada ima relativno slam stimulatorni efekat kad se samostalno dozira.[2][4][5][6]
^абRothman, R. B.; Blough, BE; Woolverton, WL; Anderson, KG; Negus, SS; Mello, NK; Roth, BL; Baumann, MH (2005). „Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration”.Journal of Pharmacology and Experimental Therapeutics.313 (3): 1361—1369.PMID15761112.doi:10.1124/jpet.104.082503.
^Wee, S.; Anderson, KG; Baumann, MH; Rothman, RB; Blough, BE; Woolverton, WL (2004). „Relationship between the Serotonergic Activity and Reinforcing Effects of a Series of Amphetamine Analogs”.Journal of Pharmacology and Experimental Therapeutics.313 (2): 848—854.PMID15677348.doi:10.1124/jpet.104.080101.
^Mehes, G (1952). „On the pharmacological effects of 1-(alpha-naphthyl)-, and 1-(beta-naphthyl)-2-aminopropane; a contribution on the problem of chemical structure and effect”.Acta physiologica Hungarica.3 (1): 137—51.PMID13050439.
^Negus, S. S.; Mello, N. K.; Blough, B. E.; Baumann, M. H.; Rothman, R. B. (2006). „Monoamine Releasers with Varying Selectivity for Dopamine/Norepinephrine versus Serotonin Release as Candidate "Agonist" Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkeys”.Journal of Pharmacology and Experimental Therapeutics.320 (2): 627—636.PMID17071819.doi:10.1124/jpet.106.107383.
Y
.PMID 17408232.doi:10.1208/aapsj0901001. 
